Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

Theodore C. Pierson; Michael S. Diamond

doi:10.1017/S1462399408000665

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

Published online by Cambridge University Press: 12 May 2008

Theodore C. Pierson and

Michael S. Diamond

Show author details

Theodore C. Pierson*: Affiliation:
Viral Pathogenesis Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892, USA.
Michael S. Diamond: Affiliation:
Departments of Medicine, Molecular Microbiology, and Pathology & Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.
*: *Corresponding author: Theodore C. Pierson, Laboratory of Viral Diseases, NIAID, NIH, 33 North Drive, Room 1E19A.2, Bethesda, MD 20814, USA. Tel: +1 301 451 7977; Fax: 1 301 451 7978; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Flaviviruses are a group of positive-stranded RNA viruses that cause a spectrum of severe illnesses globally in more than 50 million individuals each year. While effective vaccines exist for three members of this group (yellow fever, Japanese encephalitis, and tick-borne encephalitis viruses), safe and effective vaccines for several other flaviviruses of clinical importance, including West Nile and dengue viruses, remain in development. An effective humoral immune response is critical for protection against flaviviruses and an essential goal of vaccine development. The effectiveness of virus-specific antibodies in vivo reflects their capacity to inhibit virus entry and spread through several mechanisms, including the direct neutralisation of virus infection. Recent advances in our understanding of the structural biology of flaviviruses, coupled with the use of small-animal models of flavivirus infection, have promoted significant advances in our appreciation of the factors that govern antibody recognition and inhibition of flaviviruses in vitro and in vivo. In this review, we discuss the properties that define the potency of neutralising antibodies and the molecular mechanisms by which they inhibit virus infection. How recent advances in this area have the potential to improve the development of safe and effective vaccines and immunotherapeutics is also addressed.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 10 , October 2008 , e12

DOI: https://doi.org/10.1017/S1462399408000665 [Opens in a new window]
Copyright: Published by Cambridge University Press. Work by a US government employee - not in copyright in the USA.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Mackenzie, J.S., Gubler, D.J. and Petersen, L.R. (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10, S98-109CrossRef Google Scholar PubMed

2Zhang, Y. et al. (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618CrossRef Google Scholar PubMed

3Rey, F.A. et al. (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298CrossRef Google Scholar

4Modis, Y. et al. (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100, 6986-6991CrossRef Google Scholar PubMed

5Modis, Y. et al. (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79, 1223-1231CrossRef Google Scholar PubMed

6Chu, J.J. et al. (2005) Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 86, 405-412CrossRef Google Scholar PubMed

7Allison, S.L. et al. (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75, 4268-4275CrossRef Google Scholar PubMed

8Modis, Y. et al. (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319CrossRef Google Scholar PubMed

9Bressanelli, S. et al. (2004) Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 23, 728-738CrossRef Google Scholar PubMed

10Zhang, W. et al. (2003) Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10, 907-912CrossRef Google Scholar PubMed

11Allison, S.L. et al. (1999) Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol 73, 5605-5612CrossRef Google Scholar PubMed

12Wang, S., He, R. and Anderson, R. (1999) PrM- and cell-binding domains of the dengue virus E protein. J Virol 73, 2547-2551CrossRef Google Scholar PubMed

13Mackenzie, J.M. and Westaway, E.G. (2001) Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75, 10787-10799CrossRef Google Scholar PubMed

14Zhang, Y. et al. (2007) Structure of immature West Nile virus. J Virol 81, 6141-6145CrossRef Google Scholar PubMed

15Zhang, Y. et al. (2003) Structures of immature flavivirus particles. EMBO J 22, 2604-2613CrossRef Google Scholar PubMed

16Heinz, F.X. et al. (1994) Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198, 109-117CrossRef Google Scholar

17Guirakhoo, F. et al. (1991) Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol 72, 1323-1329CrossRef Google Scholar PubMed

18Mukhopadhyay, S., Kuhn, R.J. and Rossmann, M.G. (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13-22CrossRef Google Scholar PubMed

19Stadler, K. et al. (1997) Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71, 8475-8481CrossRef Google Scholar PubMed

20Mukhopadhyay, S. et al. (2003) Structure of West Nile virus. Science 302, 248CrossRef Google Scholar PubMed

21Kuhn, R.J. et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725CrossRef Google Scholar PubMed

22Kimura, T., Gollins, S.W. and Porterfield, J.S. (1986) The effect of pH on the early interaction of West Nile virus with P388D1 cells. J Gen Virol 67, 2423-2433CrossRef Google Scholar PubMed

23Gollins, S.W. and Porterfield, J.S. (1986) pH-dependent fusion between the flavivirus West Nile and liposomal model membranes. J Gen Virol 67, 157-166CrossRef Google Scholar PubMed

24Holzmann, H. et al. (1995) Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions. Arch Virol 140, 213-221CrossRef Google Scholar

25Stiasny, K. et al. (1996) Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J Virol 70, 8142-8147CrossRef Google Scholar PubMed

26Stiasny, K. et al. (2001) Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus. J Virol 75, 7392-7398CrossRef Google Scholar PubMed

27Allison, S.L. et al. (1995) Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol 69, 695-700CrossRef Google Scholar PubMed

28Eckert, D.M. and Kim, P.S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70, 777-810CrossRef Google Scholar PubMed

29Colman, P.M. and Lawrence, M.C. (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4, 309-319CrossRef Google Scholar PubMed

30Liao, M. and Kielian, M. (2005) Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 171, 111-120CrossRef Google Scholar PubMed

31Bai, F. et al. (2007) Antiviral peptides targeting the west nile virus envelope protein. J Virol 81, 2047-2055CrossRef Google Scholar PubMed

32Hrobowski, Y.M., Garry, R.F. and Michael, S.F. (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2, 49CrossRef Google Scholar PubMed

33Reeves, J.D. and Piefer, A.J. (2005) Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766CrossRef Google Scholar PubMed

34Diamond, M.S. et al. (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77, 2578-2586CrossRef Google Scholar PubMed

35Diamond, M.S. et al. (2003) Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16, 259-278CrossRef Google Scholar PubMed

36Oliphant, T. et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11, 522-530CrossRef Google Scholar PubMed

37Tesh, R.B. et al. (2002) Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 8, 245-251CrossRef Google Scholar PubMed

38Wang, T. et al. (2001) Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 167, 5273-5277CrossRef Google Scholar PubMed

39Ben-Nathan, D. et al. (2003) Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J Infect Dis 188, 5-12CrossRef Google Scholar PubMed

40Camenga, D.L., Nathanson, N. and Cole, G.A. (1974) Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 130, 634-641CrossRef Google Scholar PubMed

41Roehrig, J.T. et al. (2001) Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951, 286-297CrossRef Google Scholar PubMed

42Mathews, J.H. and Roehrig, J.T. (1984) Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 132, 1533-1537CrossRef Google Scholar

43Kreil, T.R. et al. (1997) Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110, 358-361CrossRef Google Scholar PubMed

44Kreil, T.R. et al. (1998) Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol 72, 3076-3081CrossRef Google Scholar PubMed

45Beasley, D.W. et al. (2004) Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22, 3722-3726CrossRef Google Scholar PubMed

46Vazquez, S. et al. (2002) Immune response to synthetic peptides of dengue prM protein. Vaccine 20, 1823-1830CrossRef Google Scholar PubMed

47Pincus, S. et al. (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187, 290-297CrossRef Google Scholar

48Falconar, A.K. (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144, 2313-2330CrossRef Google Scholar

49Colombage, G. et al. (1998) DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163CrossRef Google Scholar

50Chung, K.M. et al. (2007) Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 81, 9551-9555CrossRef Google Scholar PubMed

51Chung, K.M. et al. (2006) Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80, 1340-1351CrossRef Google Scholar PubMed

52Shu, P.Y. et al. (2000) Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J Med Virol 62, 224-2323.0.CO;2-C>CrossRef Google Scholar PubMed

53Churdboonchart, V. et al. (1991) Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 44, 481-493CrossRef Google Scholar PubMed

54Gibson, C.A., Schlesinger, J.J. and Barrett, A.D. (1988) Prospects for a virus non-structural protein as a subunit vaccine. Vaccine 6, 7-9CrossRef Google Scholar PubMed

55Beasley, D.W. and Barrett, A.D. (2002) Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76, 13097-13100CrossRef Google Scholar PubMed

56Oliphant, T. et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80, 12149-12159CrossRef Google Scholar PubMed

57Crill, W.D. and Chang, G.J. (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78, 13975-13986CrossRef Google Scholar PubMed

58Roehrig, J.T., Bolin, R.A. and Kelly, R.G. (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328CrossRef Google Scholar PubMed

59Roehrig, J.T., Mathews, J.H. and Trent, D.W. (1983) Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128, 118-126CrossRef Google Scholar

60Heinz, F.X. et al. (1983) A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 126, 525-537CrossRef Google Scholar PubMed

61Mandl, C.W. et al. (1989) Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol 63, 564-571CrossRef Google Scholar

62Sukupolvi-Petty, S. et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81, 12816-12826CrossRef Google Scholar PubMed

63Throsby, M. et al. (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80, 6982-6992CrossRef Google Scholar PubMed

64Oliphant, T. et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81, 11828-11839CrossRef Google Scholar PubMed

65Sanchez, M.D. et al. (2007) The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359, 336-348CrossRef Google Scholar PubMed

66Della-Porta, A.J. and Westaway, E.G. (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38, 1-19CrossRef Google Scholar PubMed

67Burton, D.R., Saphire, E.O. and Parren, P.W. (2001) A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 260, 109-143Google Scholar

68Pierson, T.C. et al. (2007) Stoichiometric requirements for antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-146CrossRef Google Scholar

69Klasse, P.J. and Sattentau, Q.J. (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83, 2091-2108CrossRef Google Scholar PubMed

70Gromowski, G.D. and Barrett, A.D. (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360CrossRef Google Scholar PubMed

71Stiasny, K. et al. (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80, 9557-9568CrossRef Google Scholar PubMed

72Morrey, J.D. et al. (2006) Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194, 1300-1308CrossRef Google Scholar PubMed

73Morrey, J.D. et al. (2007) Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 51, 2396-2402CrossRef Google Scholar

74Nybakken, G.E. et al. (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437, 764-769CrossRef Google Scholar PubMed

75Kaufmann, B. et al. (2006) West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 103, 12400-12404CrossRef Google Scholar PubMed

76Krishnan, M.N. et al. (2007) Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 81, 4881-4885CrossRef Google Scholar PubMed

77van der Schaar, H.M. et al. (2007) Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 81, 12019-12028CrossRef Google Scholar PubMed

78Gollins, S.W. and Porterfield, J.S. (1985) Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J Gen Virol 66, 1969-1982CrossRef Google Scholar PubMed

79Chu, J.J. and Ng, M.L. (2004) Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 78, 10543-10555CrossRef Google Scholar PubMed

80Anderson, R. (2003) Manipulation of cell surface macromolecules by flaviviruses. Adv Virus Res 59, 229-274CrossRef Google Scholar PubMed

81Stiasny, K., Koessl, C. and Heinz, F.X. (2003) Involvement of lipids in different steps of the flavivirus fusion mechanism. J Virol 77, 7856-7862CrossRef Google Scholar PubMed

82Stiasny, K. et al. (2002) Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH. J Virol 76, 3784-3790CrossRef Google Scholar

83Pantophlet, R. and Burton, D.R. (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739-769CrossRef Google Scholar PubMed

84He, R.T. et al. (1995) Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45, 451-461CrossRef Google Scholar

85Jennings, A.D. et al. (1994) Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169, 512-518CrossRef Google Scholar PubMed

86Mandl, C.W. et al. (2000) Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol 74, 9601-9609CrossRef Google Scholar PubMed

87Holzmann, H. et al. (1990) A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J Virol 64, 5156-5159CrossRef Google Scholar PubMed

88Jiang, W.R. et al. (1993) Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J Gen Virol 74, 931-935CrossRef Google Scholar PubMed

89Tassaneetrithep, B. et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197, 823-829CrossRef Google Scholar PubMed

90Navarro-Sanchez, E. et al. (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4, 723-728CrossRef Google Scholar PubMed

91Sakuntabhai, A. et al. (2005) A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 37, 507-513CrossRef Google Scholar PubMed

92Lozach, P.Y. et al. (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 280, 23698-23708CrossRef Google Scholar PubMed

93Davis, C.W. et al. (2006) The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem 281, 37183-37194CrossRef Google Scholar PubMed

94Davis, C.W. et al. (2006) West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 80, 1290-1301CrossRef Google Scholar PubMed

95Pokidysheva, E. et al. (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124, 485-493CrossRef Google Scholar PubMed

96Mitchell, D.A., Fadden, A.J. and Drickamer, K. (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276, 28939-28945CrossRef Google Scholar PubMed

97Gollins, S.W. and Porterfield, J.S. (1986) A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321, 244-246CrossRef Google Scholar PubMed

98Nybakken, G.E. et al. (2006) Crystal structure of the west nile virus envelope glycoprotein. J Virol 80, 11467-11474CrossRef Google Scholar PubMed

99Stiasny, K. et al. (2007) Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol 81, 11526-11531CrossRef Google Scholar PubMed

100Mehlhop, E. et al. (2005) Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79, 7466-7477CrossRef Google Scholar PubMed

101Mehlhop, E. and Diamond, M.S. (2006) Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203, 1371-1381CrossRef Google Scholar PubMed

102Meyer, K. et al. (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76, 2150-2158CrossRef Google Scholar PubMed

103Feng, J.Q., Mozdzanowska, K. and Gerhard, W. (2002) Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76, 1369-1378CrossRef Google Scholar PubMed

104Schlesinger, J.J. and Chapman, S. (1995) Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 76, 217-220CrossRef Google Scholar PubMed

105Schlesinger, J.J., Foltzer, M. and Chapman, S. (1993) The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192, 132-141CrossRef Google Scholar PubMed

106Halstead, S.B. (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60, 421-467CrossRef Google Scholar PubMed

107Rothman, A.L. (2003) Immunology and immunopathogenesis of dengue disease. Adv Virus Res 60, 397-419CrossRef Google Scholar PubMed

108Vaughn, D.W. et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181, 2-9CrossRef Google Scholar PubMed

109Halstead, S.B., Nimmannitya, S. and Cohen, S.N. (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42, 311-328Google Scholar PubMed

110Kliks, S.C. et al. (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38, 411-419CrossRef Google Scholar PubMed

111Klimstra, W.B. et al. (2005) Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 338, 9-21CrossRef Google Scholar PubMed

112Iankov, I.D. et al. (2006) Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80, 8530-8540CrossRef Google Scholar PubMed

113Huang, K.J. et al. (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176, 2825-2832CrossRef Google Scholar PubMed

114Wallace, M.J. et al. (2003) Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84, 1723-1728CrossRef Google Scholar PubMed

115Takada, A. et al. (2003) Antibody-dependent enhancement of Ebola virus infection. J Virol 77, 7539-7544CrossRef Google Scholar PubMed

116Girn, J., Kavoosi, M. and Chantler, J. (2002) Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol 83, 351-358CrossRef Google Scholar PubMed

117Littaua, R., Kurane, I. and Ennis, F.A. (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144, 3183-3186CrossRef Google Scholar PubMed

118Takeda, A., Tuazon, C.U. and Ennis, F.A. (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242, 580-583CrossRef Google Scholar PubMed

119Tamura, M., Webster, R.G. and Ennis, F.A. (1991) Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 182, 211-219CrossRef Google Scholar

120Morens, D.M. and Halstead, S.B. (1990) Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71, 2909-2914CrossRef Google Scholar PubMed

121Morens, D.M., Halstead, S.B. and Marchette, N.J. (1987) Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb Pathog 3, 231-237CrossRef Google Scholar PubMed

122Gimenez, H.B. et al. (1996) Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immunol 3, 280-286CrossRef Google Scholar PubMed

123Gimenez, H.B., Keir, H.M. and Cash, P. (1989) In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera. J Gen Virol 70, 89-96CrossRef Google Scholar PubMed

124Osiowy, C., Horne, D. and Anderson, R. (1994) Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin Diagn Lab Immunol 1, 670-677CrossRef Google Scholar PubMed

125Mady, B.J. et al. (1991) Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol 147, 3139-3144CrossRef Google Scholar PubMed

126Gould, E.A. and Buckley, A. (1989) Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70, 1605-1608CrossRef Google Scholar PubMed

127Barrett, A.D. and Gould, E.A. (1986) Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 67, 2539-2542CrossRef Google Scholar PubMed

128Schlesinger, J.J. and Brandriss, M.W. (1981) Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol 8, 103-117CrossRef Google Scholar PubMed

129Robinson, W.E. Jr., Montefiori, D.C. and Mitchell, W.M. (1988) Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1, 790-794CrossRef Google Scholar PubMed

130Halstead, S.B. and O'Rourke, E.J. (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146, 201-217CrossRef Google Scholar PubMed

131Goncalvez, A.P. et al. (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104, 9422-9427CrossRef Google Scholar PubMed

132Halstead, S.B. (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140, 527-533CrossRef Google Scholar PubMed

133Mehlhop, E. et al. (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2, 417-426CrossRef Google Scholar

134Broom, A.K. et al. (2000) Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model. J Med Virol 61, 259-2653.0.CO;2-M>CrossRef Google Scholar PubMed

135Gollins, S.W. and Porterfield, J.S. (1984) Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 65, 1261-1272CrossRef Google Scholar PubMed

136Chareonsirisuthigul, T., Kalayanarooj, S. and Ubol, S. (2007) Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 88, 365-375CrossRef Google Scholar PubMed

137Suhrbier, A. and La Linn, M. (2003) Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 24, 165-168CrossRef Google Scholar PubMed

138Hober, D. et al. (2001) Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J Infect Dis 184, 1098-1108CrossRef Google Scholar PubMed

139Lidbury, B.A. and Mahalingam, S. (2000) Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74, 8376-8381CrossRef Google Scholar PubMed

140Mahalingam, S. and Lidbury, B.A. (2003) Antibody-dependent enhancement of infection: bacteria do it too. Trends Immunol 24, 465-467CrossRef Google Scholar

141Hamdan, A. et al. (2002) Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 4, 160-162CrossRef Google Scholar

142Shimoni, Z. et al. (2001) Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 7, 759CrossRef Google Scholar PubMed

Article contents

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests